When was Edgewise Therapeutics founded?

Edgewise Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Edgewise Therapeutics located?

Edgewise Therapeutics is headquartered in Boulder, United States. It is registered at Boulder, Colorado.

How many employees does Edgewise Therapeutics have?

As of Aug 31, 2026, the latest employee count at Edgewise Therapeutics is 142.

Is Edgewise Therapeutics a funded company?

Edgewise Therapeutics is a funded company, having raised a total of $145M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Sep 17, 2019.

When was the latest funding round of Edgewise Therapeutics?

Edgewise Therapeutics' latest funding was a $***** Series C round on Dec 08, 2020, with participation from 13 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.63B in funding in 2026 to date.

Where does Edgewise Therapeutics rank among its competitors?

Edgewise Therapeutics ranks 51st amongst 925 active competitors, of which 279 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Edgewise Therapeutics?

Edgewise Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Edgewise Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Edgewise Therapeutics is a public company based in Boulder (United States), founded in 2017 by Peter Thompson. It operates as a Developer of therapeutics for skeletal and cardiac muscle diseases. Edgewise Therapeutics has raised $145M in funding from investors like USVP, Viking Global Investors and Novo Holdings. The company has 925 active competitors, including 279 funded and 231 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of therapeutics for skeletal and cardiac muscle diseases. The company designs develop and optimize therapeutic agents which are EDG-001 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, EDG-002 for treating Adult Neuromuscular Disorders, and EDG-003 for the treatment of Metabolic Disorders.

Website: edgewisetx.com
Social
Email ID: *****@edgewisetx.com
Phone Number: +1 **********
Registered Address: Boulder, Colorado

Key Metrics

Founded Year

2017

Location

Boulder, United States

Stage

Public

Total Funding

$145M in 2 rounds

Latest Funding Round

Series C, Dec 08, 2020, $*****

Investors

USVP & 13 more

Ranked

51^st among 925 active competitors

Employee Count

142 as on Aug 31, 2026

Similar Companies

Tenaya Therapeutics & 403 more

Exit Details

Public

View Edgewise Therapeutics' full profile

Edgewise Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Edgewise Therapeutics, Inc. CIN: 1710072 , United States, Active	May 16, 2017	-	-	-
EDGEWISE THERAPEUTICS, INC CIN: 821725586 , United States, Active	Dec 31, 2016	-	104 (As on Dec 31, 2024)	-

Edgewise Therapeutics got listed on Mar 26, 2021.

Click here to take a look at Edgewise Therapeutics's IPO in detail

Edgewise Therapeutics has raised a total funding of $145M over 2 rounds. Its first funding round was on Sep 17, 2019. Its latest funding round was a Series C round on Dec 08, 2020 for $*****. 13 investors participated in its latest round. Edgewise Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Edgewise Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 08, 2020	8392988	Series C	6308652	7752646	6548071	7694873
Sep 17, 2019	5437317	Series B	7794242	7610801	Novo Holdings & 1 more	Deerfield & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Edgewise Therapeutics's funding rounds and investors

The founders of Edgewise Therapeutics is Peter Thompson.

Here are the details of Edgewise Therapeutics' key team members:

Peter Thompson: Co-Founder & Chief Operating Officer of Edgewise Therapeutics and founder of 1 other company.

View details of Edgewise Therapeutics's Founder profiles and Board Members

Edgewise Therapeutics' employee count trend

Edgewise Therapeutics has 142 employees as of Aug 26. Here is Edgewise Therapeutics's employee count trend over the years:

Employee count trend for Edgewise Therapeutics

Uncover Edgewise Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Edgewise Therapeutics include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Edgewise Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
6th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	69/100
7th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
8th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
9th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100
10th	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
51st	Edgewise Therapeutics 2017, Boulder (United States), Public	Developer of therapeutics for skeletal and cardiac muscle diseases	$145M	BB Biotech, RA Capital Management & 12 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Edgewise Therapeutics's competitors? Click here to see the top ones

Edgewise Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Edgewise Therapeutics's sector:

Free

Cardiac and Vascular Disorders - Sector Report

Edition: August, 2026 (67 Pages)

View all reports related to Edgewise Therapeutics

Media has covered Edgewise Therapeutics for a total of 14 events in the last 1 year, 9 of them have been about company updates and 1 about people movement.